About the Company
We do not have any company description for Pasithea Therapeutics Corp at the moment.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KTTA News
KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two ...
Pasithea Therapeutics Corp. Wt
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Pasithea Therapeutics begins U.S. trial for cancer treatment
SOUTH SAN FRANCISCO, Calif. - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the activation of four U.S. clinical trial sites for its Phase 1 ...
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative ...
United Therapeutics Corporation (UTHR)
United Therapeutics Corp (NASDAQ:UTHR) Chairperson & CEO Martine Rothblatt has sold 30,000 shares of the company on March 22, 2024, according to a recent SEC Filing. SILVER SPRING, Md.
KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two ...
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor ...
Pasithea Therapeutics begins U.S. trial for cancer treatment
SOUTH SAN FRANCISCO, Calif. - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the activation of four U.S. clinical trial sites for its Phase 1 study ...
Pasithea Therapeutics Corp KTTA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pasithea Therapeutics Corp. (KTTA)
and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation -- ...
Loading the latest forecasts...